EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Autonomous Nanomedicine: Closing the Biological Validation Gap

Yan Jun Lin iD, Izabella Komperda

Exploration · 04.11.2026

DOI: 10.1002/exp2.70228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 04.11.2026. Verfasst von Yan Jun Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences Cornell University Ithaca New York USA. Die Arbeit nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta‐analyses and late‐stage attrition indicate biological validation is often a bottleneck. It must account for context‐dependent processes such as protein corona formation, immune recognition and cell/tissue barrier effects, which standard preclinical testing cannot always assess adequately. To address this, we propose a Design–Make–Test–Biology–Learn (DMTBL) workflow that separates biological validation from physicochemical testing and feeds human‐relevant biological results back into formulation design. We assess the capabilities required for end‐to‐end autonomy using an author‐assigned technology‐readiness evaluation with explicit criteria adapted for biomedical translation. Many of the required technologies are approaching practical deployment, including high‐throughput robotic formulation, automated physicochemical assays, predictive models for biodistribution and toxicity, and patient‐derived organoids with growing human relevance. But no closed‐loop DMTBL system has yet been demonstrated: integration sits at technology readiness level 2–3 against components at levels 3–8. The Learn step also requires a different computational stack from the Analyze step it replaces, handling imaging and multi‐parametric phenotypes rather than scalar physicochemical metrics. Three practical barriers remain: mismatched timescales between formulation and biological testing, heterogeneous data combining quantitative measurements with imaging and biological variability across platforms and donors. We set out near‐term engineering and standardization priorities within a staged roadmap that separates plausible short‐term milestones from longer‐horizon goals.

Schlagwörter

Stichwörter der Autor:innen

biological validationdrug deliverydrug discoverynanomedicineorgan‐on‐chipprotein corona

Autor:innen und Institutionen

  • Department of Biological Sciences Cornell University Ithaca New York USA.
  • Department of Mechanical Engineering Rutgers University New Brunswick New Jersey USA.

ORCID-Profile: Yan Jun Lin

Zitieren

APA

Lin, Y. J., & Komperda, I. (2026). Autonomous Nanomedicine: Closing the Biological Validation Gap. Exploration. https://doi.org/10.1002/exp2.70228

Vancouver

Lin YJ, Komperda I. Autonomous Nanomedicine: Closing the Biological Validation Gap. Exploration. 2026. doi:10.1002/exp2.70228

BibTeX
@article{Lin2026,
  author = {Lin, Yan Jun and Komperda, Izabella},
  title = {Autonomous Nanomedicine: Closing the Biological Validation Gap},
  journal = {Exploration},
  year = {2026},
  doi = {10.1002/exp2.70228}
}
Kostenlos starten →